Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 400%

Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 400%

Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 400% · Investor's Business Daily
Trade LLY on Coinbase

Eli Lilly said Thursday it will buy its diabetes treatment partner, Sigilon Therapeutics, and the biotech stock skyrocketed.